EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudiePragmatische Studie

Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study

Omesh Goyal iD, Manjeet Kumar Goyal, Bhupinder Singh, Rajdeep Singh, Prerna Goyal, Varun Mehta, Sandeep Kaushal, Ajit Sood

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70828 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Omesh Goyal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India. Hauptthemen laut MEDLINE: Constipation, Benzofurans, Serotonin 5-HT4 Receptor Agonists, Benzamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The choice of second‐line therapy in functional constipation (FC) is often empirical, owing to the lack of direct comparisons between agents with distinct mechanisms of action. Elobixibat, an ileal bile acid transporter inhibitor, and prucalopride, a selective 5‐HT 4 receptor agonist, represent two different therapeutic approaches targeting intestinal secretion and colonic motility. This study aimed to directly compare the efficacy of elobixibat and prucalopride in patients with FC.

Methods

In this multicentre, prospective, pragmatic study with blinded outcome assessment, adults meeting Rome IV criteria for FC and refractory to first‐line treatment were enrolled after a standardized run‐in period. Participants received either elobixibat or prucalopride for 8 weeks. The primary endpoint was a sustained complete spontaneous bowel movement (CSBM) response, defined as ≥ 3 CSBMs per week and an increase of ≥ 1 CSBM from baseline for at least 6 of 8 weeks. Secondary outcomes included changes in stool consistency, associated symptoms and quality of life (QoL).

Results

A total of 214 patients were included (elobixibat, n = 108; prucalopride, n = 106), with a mean age of 50.8 ± 17.4 years and 62.6% males. Elobixibat resulted in a significantly higher sustained CSBM response compared to prucalopride (55.6% vs. 33.9%; p = 0.024), indicating a clinically meaningful benefit. Both treatments significantly improved CSBM frequency and stool consistency; however, elobixibat showed greater improvement in key symptom domains, including straining ( p < 0.001), abdominal discomfort ( p = 0.005), bloating ( p = 0.011) and QoL ( p = 0.009). Both drugs were well tolerated.

Conclusions

This head‐to‐head comparative study demonstrates that elobixibat provides superior overall symptomatic relief and quality‐of‐life improvement compared with prucalopride, potentially due to its dual mechanism of action. These findings support the consideration of IBAT inhibition as a second‐line treatment option in patients with FC. Trial Registration Clinical Trials Registry of India: CTRI/2025/04/085075

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ConstipationBenzofuransSerotonin 5-HT4 Receptor AgonistsBenzamidesHumansFemaleMaleMiddle AgedProspective StudiesAdultTreatment OutcomeQuality of LifeAgedDefecationDipeptidesThiazepines

Substanzen

prucaloprideBenzofuranselobixibatSerotonin 5-HT4 Receptor AgonistsBenzamidesDipeptidesThiazepines

Autor:innen und Institutionen

  • Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.
  • Department of Internal Medicine, Cleveland Clinic Akron General, Ohio, USA.
  • Department of Gastroenterology, Amar Hospital, Patiala, Punjab, India.
  • Department of Gastroenterology, Gastro, Liver & Endoscopy Centre, Chandigarh, Punjab, India.
  • Department of Medicine, R.G. Stone Superspeciality, Ludhiana, Punjab, India.
  • Department of Pharmacology, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

ORCID-Profile: Omesh Goyal

Zitieren

APA

Goyal, O., Goyal, M. K., Singh, B., Singh, R., Goyal, P., Mehta, V., Kaushal, S., & Sood, A. (2026). Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70828

Vancouver

Goyal O, Goyal MK, Singh B, Singh R, Goyal P, Mehta V, et al. Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70828

BibTeX
@article{Goyal2026,
  author = {Goyal, Omesh and Goyal, Manjeet Kumar and Singh, Bhupinder and Singh, Rajdeep and Goyal, Prerna and Mehta, Varun and Kaushal, Sandeep and Sood, Ajit},
  title = {Elobixibat Versus Prucalopride in Functional Constipation: A Prospective Comparative Effectiveness Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70828}
}
Kostenlos starten →